Effect of Intranasal Anti-IgE Antibodies on IgE Production
Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
In this study, participants will receive either intranasal anti-IgE-antibodies (n=5) or
intranasal allergen (n=5) or intranasal placebo (n=5). Blood samples will be obtained before
nasal administration of study drugs and 3, 5 and 8 weeks thereafter. In the serum samples,
specific and total IgE levels will be assessed.